GlassScriptPhysician profile
John T English
NPI 1912347790
$5,564.67
in general payments reported to CMS, 2019-2025
33 companies · $631 in 2025
The $631 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,559 · 2020: $894 · 2021: $616 · 2022: $559 · 2023: $658 · 2024: $648 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,922 · Entertainment: $15.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,921.57 |
| Entertainment | $15.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $826.20 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $759.79 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $718.84 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $637.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $507.29 | 2019-2025 | Jardiance, Glyxambi, Synjardy |
| Janssen Pharmaceuticals, INC | $441.74 | 2019-2025 | Spravato |
| Pfizer INC. | $312.95 | 2019-2025 | |
| Amarin Pharma, INC. | $152.86 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $147.75 | 2019-2021 | |
| Amgen INC. | $145.88 | 2019-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $110.62 | 2019-2024 | Capvaxive |
| Kowa Pharmaceuticals America, INC. | $70.93 | 2019-2021 | |
| Abbvie INC. | $67.69 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.15 | 2021-2023 | |
| Allergan, INC. | $60.48 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $59.15 | 2020-2023 | |
| Sanofi Pasteur INC. | $58.32 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $44.49 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $42.19 | 2019-2024 | Eliquis |
| Nestle Healthcare Nutrition INC. | $40.93 | 2021-2023 | |
| Astellas Pharma US INC | $40.09 | 2019-2023 | Veozah |
| Axsome Therapeutics, INC. | $38.69 | 2023 | Auvelity |
| Exact Sciences Corporation | $33.99 | 2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $32.47 | 2024 | Gemtesa |
| Dexcom, INC. | $32.04 | 2022-2023 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $18.12 | 2020 | |
| Aytu Biopharma, INC. | $15.85 | 2019 | |
| Optos, INC. | $15.79 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.53 | 2025 | Xifaxan |
| Abbott Laboratories | $14.52 | 2019 | |
| Kaleo, INC. | $14.31 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.01 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John English listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.